Cold Agglutinin Disease Pipeline Insight, 2025: Advancing Beyond Supportive Care with Targeted Therapies | DelveInsight

The treatment landscape for Cold Agglutinin Disease (CAD), a rare autoimmune hemolytic anemia characterized by the destruction of red blood cells at low temperatures, is undergoing a significant transformation, shifting from non-specific, supportive approaches toward more targeted and disease-modifying interventions. CAD is primarily mediated by cold-reactive autoantibodies, usually IgM, which activate the classical complement pathway, resulting in chronic hemolysis and significant morbidity.

Traditionally, CAD has been managed with thermal protection, corticosteroids, or rituximab-based regimens, with variable efficacy and frequent relapses. However, advances in immunopathology have paved the way for novel therapies that directly inhibit the complement cascade, modulate B-cell activity, or target upstream triggers of hemolysis.

DelveInsight's "Cold Agglutinin Disease - Pipeline Insight, 2025" offers an in-depth analysis of the current R&D pipeline, covering clinical and preclinical assets under development for CAD. Companies such as Sanofi, Bioverativ, Alexion Pharmaceuticals, Novartis, and Swedish Orphan Biovitrum (Sobi) are driving innovation with promising candidates like sutimlimab (Enjaymo), pegcetacoplan, and other complement inhibitors aimed at reducing hemolysis and improving quality of life.

The report profiles these emerging therapies by mechanism of action, development stage, and clinical trial design, while also examining evolving regulatory strategies and biomarker utilization for more targeted enrollment. It also explores strategic collaborations, licensing deals, and commercial outlooks that are shaping the future CAD therapeutic landscape.

As scientific understanding deepens and clinical research progresses, the expanding CAD pipeline signals a paradigm shift from symptom control to mechanism-based, long-term solutions, offering renewed optimism for patients affected by this chronic and debilitating condition.

Interested in learning more about the current treatment landscape and the key drivers shaping the cold agglutinin disease pipeline? Click here: https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cold Agglutinin Disease Pipeline Report
• DelveInsight's cold agglutinin disease pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for cold agglutinin disease treatment.
• The leading cold agglutinin disease companies include Apellis Pharmaceuticals, Swedish Orphan Biovitrum, Novartis, Incyte Corporation, Bioverativ, Novartis Pharmaceuticals, and others are evaluating their lead assets to improve the cold agglutinin disease treatment landscape.
• Key cold agglutinin disease pipeline therapies in various stages of development include BIVV020, Iptacopan, and others.
• In May 2025, Riliprubart (SAR445088), a potential successor to ENJAYMO (sutimlimab-jome) for Cold Agglutinin Disease, showed promise in maintaining effective drug levels with a fixed dose administered once every three months. This dosing strategy was identified using modeling of existing clinical trial data and confirmed in a Phase I study involving nine CAD patients.
• In October 2024, Sanofi struck a deal to sell Enjaymo, its treatment for cold agglutinin disease, to Recordati for a potential $1 billion. Under the agreement, the Italian pharmaceutical company will pay Sanofi $825 million upfront for global rights to the biologic, with the possibility of an additional $250 million in milestone payments. Enjaymo, a humanized monoclonal antibody, treats the rare autoimmune disorder by reducing the risk of hemolysis in patients.

Request a sample and discover the recent breakthroughs happening in the cold agglutinin disease pipeline landscape at https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cold Agglutinin Disease Overview
Cold Agglutinin Disease (CAD) is a rare, chronic autoimmune hemolytic anemia in which the body's immune system mistakenly produces cold-reactive autoantibodies-usually IgM-that bind to red blood cells at low temperatures. This binding activates the classical complement pathway, leading to red blood cell destruction (hemolysis), anemia, fatigue, acrocyanosis, and other systemic symptoms, particularly in cold environments.

CAD is typically idiopathic but can also be secondary to underlying infections, lymphoproliferative disorders, or autoimmune conditions. Unlike warm autoimmune hemolytic anemia, CAD does not respond well to corticosteroids, and treatment has traditionally focused on supportive care such as thermal protection and off-label immunosuppressants or rituximab-based regimens.

Recent advances in understanding the disease mechanism, particularly the role of the complement system, have led to the development of targeted therapies, such as C1s inhibitors (e.g., sutimlimab), that offer more effective and durable disease control. With growing awareness, improved diagnostics, and an expanding therapeutic pipeline, the management of CAD is shifting toward precision medicine and improved patient outcomes.

Find out more about cold agglutinin disease medication at https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cold Agglutinin Disease Treatment Analysis: Drug Profile
BIVV020: Bioverativ (Sanofi)
BIVV020 is a humanized monoclonal antibody developed by Bioverativ, a Sanofi company, targeting complement component C1s. A Phase 1b clinical trial has been completed, assessing its safety and tolerability in adults with Cold Agglutinin Disease (CAD). The trial's primary goal was to evaluate adverse events as a measure of safety, while secondary objectives included assessing the drug's impact on complement-mediated hemolysis, as well as its pharmacokinetic, pharmacodynamic, and immunogenic profiles.

Iptacopan: Novartis Pharmaceuticals
Iptacopan is an oral, first-in-class Factor B inhibitor being developed by Novartis for CAD. It works by selectively targeting the alternative complement pathway, binding to Factor B, and inhibiting the formation of C3 convertase. This results in reduced downstream activation, including suppression of C5 convertase, C3a/C5a anaphylatoxins, and membrane attack complex formation. Unlike terminal complement inhibitors, Iptacopan preserves classical and lectin pathway activity, potentially lowering the risk of infections such as meningococcal disease. The therapy is currently in Phase II clinical trials for CAD.

Learn more about the novel and emerging cold agglutinin disease pipeline therapies at https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cold Agglutinin Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Cold Agglutinin Disease Pipeline Report
• Coverage: Global
• Key Cold Agglutinin Disease Companies: Apellis Pharmaceuticals, Swedish Orphan Biovitrum, Novartis, Incyte Corporation, Bioverativ, Novartis Pharmaceuticals, and others.
• Key Cold Agglutinin Disease Pipeline Therapies: BIVV020, Iptacopan, and others.

Dive deep into rich insights for drugs used for cold agglutinin disease treatment, visit: https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cold Agglutinin Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cold Agglutinin Disease Pipeline Therapeutics
6. Cold Agglutinin Disease Pipeline: Late-Stage Products (Phase III)
7. Cold Agglutinin Disease Pipeline: Mid-Stage Products (Phase II)
8. Cold Agglutinin Disease Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.